The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1711
ISSUE1711
September 16, 2024
Roflumilast Cream (Zoryve) for Atopic Dermatitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Roflumilast Cream (Zoryve) for Atopic Dermatitis
September 16, 2024 (Issue: 1711)
The FDA has approved a 0.15% cream formulation
of the phosphodiesterase-4 (PDE4) inhibitor
roflumilast (Zoryve – Arcutis) for topical treatment of
mild to moderate atopic dermatitis (AD) in patients
≥6 years old. Roflumilast is the second...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.